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A B S T R A C T
There is no ideal tumour marker at present. The clinical application of CYFRA 21-1 is possible once a thorough stan-
dardisation process is carried out. Standardisation is achieved by determining the reference range in asymptomatic pop-
ulation, benign and malignant lung diseases, and benign and malignant diseases of other organs. Furthermore, it
depends on knowledge of research population characteristics, patient medical histories and individual diagnostic proce-
dure results, the size of research target samples and the clinically defined control groups. The cut-off level of CYFRA 21-1
for non-small cell lung cancer (NSCLC) is 1.72 ng/mL in the Croatian population. It is based on the clinically applicable
sensitivity of 78% and specificity of 95% in benign lung diseases. The cut-off value is verified by clinical findings. For cli-
nicians the level of CYFRA 21-1 is an early sign of NSCLC in relation to all the benign lung diseases and all the benign
diseases of other organs, of which it was confirmed that they can influence the above level, provided that NSCLC is veri-
fied using standard diagnostic methods. The level of CYFRA 21-1 is also influenced by the time of sampling in relation
to other diagnostic invasive procedures. The marker is clinically applicable if clinical findings verify it; otherwise, it is
useless. This research has involved 343 healthy persons, 474 patients with a benign disease and 4440 patients with a ma-
lignant disease, 2453 of whom suffer from NSCLC. The sensitivity of CYFRA 21-1 in NSCLC is 78%, in squamous cell
lung cancer (SQC) 84.6%, in adenocarcinomas (AD) 74.3% and in large cell lung cancer (LCC) 75.3%. The level of
CYFRA 21-1 differs significantly between healthy persons, benign and malignant diseases (p<10–3). There are differen-
ces between the three histological types of NSCLC (p<10–6) and according to T and N (p<10–3). The level of CYFRA 21-1
prompts clinicians to repeat the clinical procedure during diagnosis, and helps to detect the disease earlier and impleme-
nt treatment in NSCLC. We have achieved high concordance between marker findings and clinical diagnostic.
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Introduction
In the last few decades lung cancer has become the
leading cause of death from cancer by comparison with
breast, pancreas, prostate and colon cancer taken toget-
her.1 Moreover, almost 90% of lung tumours are carcino-
mas. The survival rate generally depends on individual
histological types, the stage of the disease and individual
treatment durations. Lung cancer incidence data indica-
tes that small cell lung cancer (SCLC) comprises approxi-
mately 20% of cases, large cell lung cancer (LCC) and
non-differentiated carcinomas 9%, and that the rate of
both squamous cell lung cancer (SQC) and adenocarcino-
mas (AD) is gender-related. More specifically, 44% of
lung cancers in males are SQC, while 28% are AD. In fe-
males, however, 25% are SQC and 42% AD2. The latest
data published in 2005 reveal 2988 newly diagnosed ca-
ses of lung cancer in the Republic of Croatia, of which
2329 are diagnosed in males and 659 in females of all
ages3. According to the International Agency for Re-
search of Cancer (IARC) which compares the mortality
rates in fifty countries, in 2002 Croatia’s lung cancer mor-
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tality rate amounted to 65.3 per 100.000 in males (fourth
place) and 9.7 per 100.000 in females4. Our experience
shows that the percentage of AD has been growing in the
last few years.
Modern approaches to diagnostics and treatment (e.g.
surgery, oncological treatments and immunotherapy) ha-
ve not stopped the disease in the last decades, although
they do remain the patients’ only support. Today’s clini-
cal practice is strengthened by insights from the field of
molecular biology; namely, patients of the same gender
and age group, exposed to the same etiological factors
and suffering from the same histological type of tumour
in the same stage have completely different disease cour-
ses and survival rates. Furthermore, research into DNA
mutations implies various types of changes in multiple
loci5,6. Lung cancer is both a polygenetically determined
disease and a multifactorial disorder7–10.
Tumour markers are the product of tumourous or
normal cells, which are used to study their biological cha-
racteristics.
Human variation is the interaction of genetic and eco-
logical factors. Genetic studies of complex traits enable
researchers to collect specific data on human variability
within the framework of biomedical studies, and data on
complex phenotypes11. Furthermore, such studies contri-
bute to the quality of population specific databases with
referential values necessary for direct medical care. In
1997 an interdisciplinary team of clinicians and molecu-
lar biologists was formed in the Cancer Genetics Labora-
tory of the Jordanovac University Hospital for Pulmo-
nary Diseases in Zagreb, Croatia. Their mission was to
make molecular knowledge of lung tumour characteris-
tics clinically applicable. Their first task was to introduce
tumour markers to lung cancer treatment as a clinical
procedure equal to the others. The then available data of
other studies indicated that CYFRA 21-1 was a useful
marker in NSCLC12–19. The application of the cut-off va-
lue suggested by the producer failed to produce a clini-
cally satisfactory sensitivity in the Croatian population.
This, obviously, required the standardisation of markers
because determining the reference range is based on di-
agnostic sensitivity and specificity in respect of the medi-
cal conditions of analysis, the available diagnostic data
on patients, total sample size,20 population characteris-
tics and the differences between well defined groups.
Cytokeratins are the building units of the cytoskele-
ton that remain intact during the transformation of nor-
mal cells into tumourous cells, which allows their use as
tumour markers21. Their biological activity changes in
tumour cells. Namely, modifications, such as phospho-
rylation, glycosylation and transglutamination, start af-
fecting the N- and C- terminal parts of protein molecules,
and lead to the increase in the solubility and reorganisa-
tion of their filaments, which includes the process of
apoptosis22–24. The significance of apoptosis in the degra-
dation of cytokeratins and the origin of soluble fragments
in circulation remains unclear at this point. Cytokeratins
are insoluble in the cytoskeleton while soluble in circula-
tion, where they are detectable as partially degraded
fragments of individual proteins that make up small
complexes – apoptotic bodies25 or they become large poly-
meric protein complexes amplifying apoptotic signals.26
Cytokeratin half-life in circulation ranges between 10
and 15 hours depending on the size of fragments. On the
other hand, the half-life of cytokeratin 19 is 12 hours.
The most frequent mechanisms that participate in the
emergence of soluble cytokeratins are proteolytic degra-
dation of cytokeratins in dying cells, abnormal mitosis,
the overproduction of monomeric cytokeratin polypepti-
des from proliferating cells, apoptosis and/or neovascula-
risation27.
The aim of this study was to standardise the CYFRA
21-1 marker in Croatian population, which would help
clinicians detect NSCLC earlier and in differential diag-
nosis.
Subjects and Methods
Between December 1997 and June 2007 CYFRA 21-1
levels in the blood of over 27000 patients were measured
in the Cancer Genetics Laboratory of the Jordanovac
University Hospital for Pulmonary Diseases in Zagreb.
This research involved 4914 patients and 343 healthy in-
dividuals. The patient samples were collected during
standard clinical diagnostics preceding treatment, while
strictly adhering to the ethical principles of medical re-
search. The subjects were sorted into 27 groups. There
were 2381 patients with NSCLC (Table 1), of whom 2050
(stages IA–IIIAN2) were surgically treated after diagno-
sis, including stage IIIA patients receiving neoadjuvant
therapy. The NSCLC group comprises three histological
types of lung cancer – SQC, AD and LCC – and 72 pa-
tients with non-differentiated NSCLC, used in the con-
struction of the ROC curve. There were 80 carcinoid tu-
mours, 169 SCLC, 474 patients with benign diseases and
1738 patients with malignant diseases of other organs
(Table 2). The healthy individuals had no proof of suffer-
ing either from a benign or malignant disease.
All NSCLC patients underwent radiological analysis,
computed tomography (CT) of the thorax and abdomen,
while patients with an AD larger than 1 cm also under-
went a CT scan of the head and magnetic resonance ima-
ging (MRI) if judged necessary. Furthermore, in bron-
choscopy, catheter aspirations of the upper airway were
performed to obtain antibiograms, as well as brushing
and tumour biopsy or transbronchial aspirations. A small
number of subjects underwent transthoracic needle bi-
opsy due to the above methods having been insufficient.
The nodal status (N) was determined in 85% of patients
using CT. With the purpose of assessing N2 (>1.5 cm) in
the last few years mediastinoscopy and video-assisted
thoracoscopy (VATS) were also performed, with which
operability was also assessed. In 7% of patients with
ground glass opacities (GGOs) the diagnosis of primary
lung cancer was made by means of diagnostic minithora-
cotomy performed simultaneously with the surgical pro-
cedure. The assessment of bone metastases in the advan-
ced stages of the disease was done by scinthigraphy. The
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histological classification of lung tumours was carried
out according to the current tumour classification of the
World Health Organization (WHO) and the Internatio-
nal Association for the Study of Lung Cancer (IASLC).2,28
The surgical pathologic staging (pTNM) was done after
examining the total removed tissue according to the
TNM classification of malignant tumours,29 and follow-
ing the guidelines of the Union Internationale Contre le
Cancre and the American Joint Committee on Cancer.30,31
From December 1997 to June 2000 the analysis was
first conducted on the ES-300 system by enzyme-linked
immunoassay using the commercial kit Enzymun-test
CYFRA 21-1 (Boehringer Mannheim GmbH, Germany).
CYFRA 21-1 was then measured on the Elecsys 2010 sys-
tem by electrochemiluminescence immunoassay (Roche
Diagnostics, Germany). In doing the analyses, the manu-
facturers’ instructions and recommendations were stric-
tly followed. Joining the results obtained through the
two methods is considered methodologically correct be-
cause the results correlate once compared.
The cut-off value was determined using the ROC cur-
ve with the help of MedCalc v. 9.2.1.0 (MedCalc Software,
Belgium). The statistical analysis was conducted with
the help of Statistica 6.0 software package (Statsoft,
USA). Since marker levels were not distributed normally,
the results are presented as medians and 25th and 75th
percentiles. In addition, nonparametric methods were al-
so used, and the differences are considered significant if
p<0.05. For the purpose of analysing the differences be-
tween two independent groups the Mann-Whitney U-test
was used, while for more than two independent groups
the Kruskal-Wallis ANOVA was used. For the separation
of NSCLC in solitary lung nodules and metastases a dis-
criminant analysis was employed.
Results
The sensitivity and specificity of CYFRA 21-1 were
determined on the basis of the level measured while sus-
pecting lung cancer or making diagnosis in 2990 subjects
from the reference population consisting of 343 healthy
subjects, 164 patients with benign diseases of the lung,
and 2453 NSCLC patients (1250 SQC, 929 AD, 202 LCC
and 72 non-differentiated NSCLC). With the aim of ulti-
mately determining the optimal upper level of the refer-
ence range (cut-off) the ROC curve was used. In healthy
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TABLE 1
LUNG CANCER PATIENT CHARACTERISTICS
Variables Number (%)
Gender
Males
Females
1784 (76.4)
597 (23.6)
Age (mean years  SD)
Males
Females
65  9
63  10
SQC AD LCC
Stage and tumour histology
IA
IB
IIBT2
IIBT3
IIIAN1
IIIAN2
IIIB
IV
All
116 (9.3)
562 (44.9)
83 (6.6)
92 (7.4)
34 (2.7)
182 (14.6)
46 (3.7)
135 (10.8)
1250 (100)
160 (17.2)
366 (39.4)
60 (6.5)
62 (6.7)
18 (1.9)
149 (16)
34 (3.7)
80 (8.6)
929 (100)
10 (4.9)
68 (33.7)
20 (9.9)
23 (11.4)
9 (4.5)
36 (17.8)
6 (2.9)
30 (14.8)
202 (100)
Surgery
BID
BSD
LID
LIS
LSD
LSS
PD
PS
RLM
All
154 (7.5)
64 (3.1)
299 (14.6)
453 (22.1)
373 (18.2)
380 (18.5)
111 (5.4)
173 (8.4)
43 (2.1)
2050 (100)
individuals, the CYFRA 21-1 median was 0.88 ng/mL and
the 95th percentile 1.49 ng/mL, while in benign lung dis-
eases the median was 1.12 ng/mL and the 95th percentile
1.72 ng/mL. Subjects with benign diseases of the lung
were used for the calculation of the specificity in relation
to subjects with NSCLC who were used for determining
the sensitivity. Figures 1a–f presents the values of the
ROC curves of each groups. The cut-off value of CYFRA
21-1 in NSCLC of 1.72 ng/mL was selected at 95% of the
specificity of benign lung diseases. In other words, this
means that it distinguishes healthy individuals and those
with a benign lung disease from subjects who suffer from
a malignant lung disease well. The sensitivity of CYFRA
21-1 in NSCLC was 78%, 84.6% in SQC, 74.3% in AD and
75.3% in LCC. According to the disease stages and overa-
ll, the highest sensitivity was observed in SQC patients
(Figure 2).
The difference between two measurements of CYFRA
21-1 during diagnostics (3–9 weeks) of NSCLC possesses
a much greater discriminatory power than single measu-
rements. It is possible to separate NSCLC from benign
lung lesions, lung metastases and Hodgkin’s disease with
an accuracy of 91% using the second measurement of
CYFRA 21-1 and the difference between the two measu-
rements. A canonical analysis was also carried out, with
the help of which the discriminant functions were obtai-
ned (Eigen value=0.8223, canonical R=0.6718, Wilks
lambda=0.5487, X2=256.859, df=2, p=1  10–4). The
discriminant function of the difference between the two
measurements was –0.9756 and of the second measure-
ment of CYFRA 21-1 –0.8181. This suggests that the dif-
ference between the two measurements is highly signifi-
cant, as well as that the contribution of the second
measurement is substantial.
The serum level of CYFRA 21-1 differs significantly
between all the 26 groups of patients and the group of
healthy individuals (Kruskal-Wallis ANOVA, p<10–3).
The highest median was observed in NSCLC (3.08
ng/mL) and in non-differentiated NSCLC (2.75 ng/mL),
followed by SCLC (2.64 ng/mL). In benign diseases the
median ranges between 0.87 ng/mL and 1.19 ng/mL with
the exception of 1.98 ng/mL in severe septic conditions.
In the groups of other malignant diseases the median va-
lues of CYFRA 21-1 range between 0.91 ng/mL in urinary
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TABLE 2
CYFRA 21-1 LEVEL IN PATIENTS WITH BENIGN AND MALIGNANT DISEASES OTHER THAN SQUAMOUS CELL LUNG CARCINOMAS,
LUNG ADENOCARCINOMAS AND LARGE CELL LUNG CARCINOMAS
Group N Median (ng/mL) 25th 75th 95th
Healthy persons 343 0.88 0.69 1.21 1.49
Benign diseases of the lung 164 1.12 0.77 1.39 1.72
Benign diseases of other organs 30 1.60 1.02 1.60 2.10
Pleural empyema 51 1.15 0.80 1.62 4.32
Benign lung and mediastinal tumours 153 1.19 0.83 1.42 1.91
Benign breast diseases 31 0.88 0.74 1.01 1.59
Severe septic condition 45 1.98 1.46 4.88 10.07
Larynx cancer 161 1.98 1.49 4.43 8.61
Urinary bladder cancer 132 0.91 0.77 3.73 6.43
Cancer of the prostate 64 1.42 1.12 1.58 2.78
Renal cancer 112 1.23 0.94 1.54 1.89
Colon cancer 102 1.23 1.06 1.45 1.81
Sarcoma 33 1.20 1.01 1.34 2.06
Melanoma 31 1.29 0.89 1.72 2.21
Seminoma 150 1.08 0.77 1.43 1.95
Thyroid carcinoma 51 1.43 1.06 2.23 3.01
Cancer of the ovary and uterus 100 1.59 1.12 1.94 3.43
Breast cancer 102 2.25 1.11 3.15 12.51
Esophageal cancer 98 1.86 1.32 2.74 12.84
Mesothelioma 37 1.66 1.12 2.73 17.37
Mediastinal cancer 59 1.29 1.03 1.59 3.65
Metastases to the lung 289 1.10 0.81 1.36 1.63
Lymphoproliferative tumours 217 1.00 0.74 1.33 1.72
Carcinoid tumour 80 1.22 0.95 1.78 4.34
Small cell lung cancer 169 2.64 1.56 4.23 16.68
Undifferentiated NSCLC 72 2.75 1.62 4.46 18.50
NSCLC – non-small cell lung cancer, 25th – 25th percentile, 75th – 75th percentile, 95th – 95th percentile
bladder cancer and 2.25 ng/mL in breast cancer (Table
2). The median value of CYFRA 21-1 in healthy subjects
is 0.88 ng/mL without any significant difference between
males and females.
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Fig. 1. Receiver operating characteristics (ROC) curves comparing the level of CYFRA 21-1 in persons without malignant diseases(spec-
ificity) and non-small cell lung carcinoma patients (sensitivity). a) Healthy and non-small cell lung carcinoma patients (n=343, 2453).
The area under the ROC curve was 0.935, standard error 0.005, 95% confidence interval 0.925 to 0.943, significance level p (area=0.5)
0.0001. b) Patients with benign diseases of the lung and non-small cell lung carcinoma patients (n=164, 2453). The area under the ROC
curve was 0.903, standard error 0.008, 95% confidence interval 0.891 to 0.914, significance level p (area=0.5) 0.0001. c) Healthy, patien-
ts with benign diseases of the lung (n=507) and non-small cell lung carcinoma patients (n=2453). The area under the ROC curve was
0.924, standard error 0.005, 95% confidence interval 0.914 to 0.934, significance level p (area=0.5) 0.0001. d) Patients with benign dis-
eases of the lung and squamous cell lung carcinoma (n=164,1250). The area under the ROC curve was 0.934, standard error 0.007,
95% confidence interval 0.920 to 0.947, significance level p (area=0.5) 0.0001. e) Patients with benign diseases of the lung and lung ade-
nocarcinoma (n=164,929). The area under the ROC curve was 0.889, standard error 0.010, 95% confidence interval 0.869 to 0.900, sig-
nificance level p (area=0.5) 0.0001. f) Patients with benign diseases of the lung and large cell lung carcinoma (n=164,202).The area un-
der the ROC curve was 0.897, standard error 0.016, 95% confidence interval 0.861 to 0.926, significance level p (area=0.5) 0.0001.
During diagnostics the median and interquartile range
of CYFRA 21-1 in SQC were 3.86 ng/mL and 2.16–10.29
ng/mL, in AD 2.51 ng/mL and 1.70–4.48 ng/mL, and in
LCC 2.77 ng/mL and 1.74–5.80 ng/mL. CYFRA 21-1 leve-
ls differ between the various histological types of lung
cancer (Kruskal-Wallis ANOVA, p<10–3), with values in
SQC higher than in AD and LCC. Moreover, there are sig-
nificant differences between SQC and AD, as well as be-
tween SQC and LCC (Mann-Whitney U-test, p<10–6,
p=1  10–6), but there are no differences between AD and
LCC. CYFRA 21-1 median values and interquartile ran-
ges increase according to stage in SQC, AD and LCC (Ta-
ble 3). According to Kruskal-Wallis ANOVA, the level in-
crease depending on stage is significant (SQC and AD
p<10–3, LCC p<10–4) (Figures 3–5). This difference is
more pronounced between stages IA and IB in all the
groups in respect of the other stages. Finally, the differ-
ence between all the stages is greatest in SQC (Table 4).
The level of CYFRA 21-1 differs significantly accordi-
ng to the T and N stages (from the TNM classification)
between SQC, AD and LCC (Kruskal-Wallis ANOVA,
p<10–3) (Table 5).
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Fig. 2. Sensitivity of CYFRA 21-1 by histological type and stage of non-small cell lung cancer. SQC – squamous cell carcinomas,
AD – adenocarcinomas, LCC – large cell carcinomas.
TABLE 3
CYFRA 21-1 DISTRIBUTION IN NON-SMALL CELL LUNG CANCER
SQC AD LCC
Stage N
Median
(ng/mL)
25th 75th N
Median
(ng/mL)
25th 75th N
Median
(ng/mL)
25th 75th
IA 116 2.11 1.69 2.59 160 1.85 1.39 2.19 10 2.35 1.72 3.3
IB 562 3.3 1.94 5.4 366 2.48 1.68 3.43 68 2.06 1.55 3.13
IIBT2N1 83 4.36 2.05 8.66 60 3.39 2.15 5.12 20 2.47 1.38 4.09
IIBT3N0 92 6.18 3.52 11.68 62 3.35 2.14 7.68 23 3.21 1.97 6.59
IIIAT3N1 34 9.36 3.76 18.13 18 7.94 2.78 13.4 9 3.03 2.37 9.4
IIIAN2 182 6.18 2.74 17.2 149 3.5 1.82 9.17 36 2.92 1.65 5.19
IIIB 46 6.64 2.53 15.31 34 5.24 2.49 12.82 6 3.13 2.83 6.68
IV 135 39.8 11.05 98.7 80 6.5 2 27.54 30 8.55 4.5 32.34
SQC – squamous cell carcinomas, AD – adenocarcinomas, LCC – large cell carcinomas, 25th – 25 th percentile, 75 th – 75 th percentile
Fig. 3. CYFRA 21-1 serum level distribution in 1250 patients with
squamous cell lung carcinoma by stage
(Kruskal-Wallis ANOVA, p<10–3).
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Fig. 4. CYFRA 21-1 serum level distribution in 929 patients with
lung adenocarcinoma by stage (Kruskal-Wallis ANOVA, p<10–3).
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Fig. 5. CYFRA 21-1 serum level distribution in 202 patients with
large cell lung carcinoma by stage
(Kruskal-Wallis ANOVA, p<10–4).
TABLE 4
STATISTICAL DIFFEENCE OF CYFRA 21-1 LEVELS BETWEEN THE STAGES OF SQUAMOUS CELL LUNG CARCINOMAS, LUNG
ADENOCARCINOMAS AND LARGE CELL LUNG CARCINOMAS TESTED BY MANN-WHITNEY U-TEST
Stage Stage p SQC p AD p LCC
IA
IB
IIBT2N1
IIBT3N0
IIIAT3N1
IIIAN2
IIIB
IV
<10–6
<10–6
<10–6
<10–6
<10–6
<10–6
<10–6
<10–6
<10–6
<10–6
<10–6
<10–6
<10–6
<10–6
NS
NS
NS
NS
NS
NS
1.6  10–3
IB
IIBT2N1
IIBT3N0
IIIAT3N1
IIIAN2
IIIB
IV
1.5  10–2
<10–6
1  10–6
<10–6
7.8  10–5
<10–2
1.3  10–4
1.5  10–4
2.3  10–5
<10–6
2  10–6
<10–6
NS
9.4  10–3
5.3  10–3
2.6  10–2
NS
<10–6
IIBT2N1
IIBT3N0
IIIAT3N1
IIIAN2
IIIB
IV
4. 4  10–3
1.4  10–3
3  10–3
4  10–2
<10–6
NS
8.6  10–3
NS
1.7  10–2
1  10–2
NS
NS
NS
NS
1  10–3
IIBT3N0
IIIAT3N1
IIIAN2
IIIB
IV
NS
NS
NS
<10–6
2.4  10–2
NS
4.9  10–2
8.4  10–3
NS
NS
NS
7.1  10–3
IIIAT3N1
IIIAN2
IIIB
IV
NS
NS
6  10–6
NS
NS
NS
NS
NS
NS
IIIAN2
IIIB
IV
NS
<10–6
NS
5.3  10–3
NS
3.7  10–4
IIIB IV 1  10–6 NS NS
SQC – squamous cell carcinomas, AD – adenocarcinomas and LCC – large cell carcinomas, NS – nonsignificant
Discussion
Tumour markers are applicable in clinical practice if
they contribute to: risk assessment, early detection, diag-
nosis, disease monitoring, prognosis, the evaluation of
patients’ response to therapy, and the prediction of the
course of the disease. If a number of the above traits are
clinically confirmed, tumour markers can become part of
clinical procedure. Markers provide insight into the cour-
se of the disease based on their concentration or the
number and type of genetic changes detected. As such,
they help clinicians to make a diagnosis much earlier
and, thus, select the most appropriate modality of treat-
ment. They are not to be viewed as a self-sufficient clini-
cal diagnostic analysis, although their import for the im-
provement of diagnostics and currently available thera-
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TABLE 5
STATISTICAL DIFFEENCE OF CYFRA 21-1 LEVELS BETWEEN
THE T AND N FROM TNM CLASSIFICATION IN SQUAMOUS
CELL LUNG CARCINOMAS, LUNG ADENOCARCINOMAS AND
LARGE CELL LUNG CARCINOMAS TESTED BY MANN-WHITNEY
U-TEST
T/N T/N p SQC p AD p LCC
T1 T2 <10–6 <10–6 NS
T1 T3 <10–6 <10–6 1.9  10–2
T1 T4 <10–6 <10–6 NS
T2 T3 <10–6 <10–6 3.8  10–5
T2 T4 <10–6 <10–6 NS
T3 T4 NS <10–6 NS
N0 N1 <10–6 <10–6 1.4  10–4
N0 N2 <10–2 <10–6 2.1  10–3
N0 N3 <10–6 4  10–2 <10–2
N1 N2 2  10–6 4.6  10–3 NS
N1 N3 7.4  10–5 NS <10–2
N2 N3 2.2  10–2 NS <10–2
NS – nonsignificant, SQC – squamous cell carcinomas, AD –
adenocarcinomas, LCC – large cell carcinomas
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example of complete response to therapy and a stable disease.
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Fig. 7. CYFRA 21-1 level in the longitudinal follow-up of a patient with squamous cell lung carcinoma, stage IB T2N0M0. CYFRA 21-1
level during diagnosis above the referral range of the population suggesting NSCLC (biological signal). In this longitudinal follow-up,
the level of CYFRA 21-1 suggest a local relapse 3 months prior the standard clinical methods. Both the operation of the primary tumour
and reoperation were performed in the same stage of the disease due to the marker.
pies is tremendous. Marker levels are patient-specific
and can be interpreted only with the help of clinical data.
If interpreted well by a skilled clinician, markers have a
diagnostic and prognostic significance, and can help to
guide checkup times and therapy selection. With the pur-
pose of applying markers in clinical practice, it is essen-
tial to define all population characteristics that either do
or may potentially influence their level or dynamics in
healthy individuals, and the sample size involved in the
research, as well as to clinically define the control groups
of primarily benign lung diseases that are expected to
have a dynamics different from the dynamics of the heal-
thy population. This is the basis for determining the refe-
rence range. Respecting this marker standardisation
procedure, the first standardisation of serum markers
for lung cancer in Croatia was done in 1998. Markers
have been included in clinical procedure improving cur-
rently available treatment methods (diagnostics, surgery,
oncology) ever since. Moreover, the approach to patients
has been individualised through evaluating all the anam-
nestic and diagnostic parameters that can influence mar-
ker levels. They are defined on a marker referral (as part
of standardised laboratory documentation). This allows
an earlier diagnosis to be suggested based on the marker.
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The selection of patients who require marker analysis is
done by internists-pulmonologists; further marker mea-
surements are recommended by laboratory physicians
based on the initial results. Laboratory findings consist
of a tumour marker value and an interpretation of the
same assessing both the »biological activity of the tu-
mour« and the patient’s clinical status (i.e. stable dis-
ease, partial response to therapy and progressive dis-
ease). Being familiar with marker dynamics in the
healthy population and subjects with benign pulmonary
diseases and diseases of other organs has facilitated the
elimination of the existing shortcomings of marker appli-
cation in clinical practice.
The clinically applicable CYFRA 21-1 reference range
of 0–1.72 ng/mL reflects the difference between the mar-
ker levels of the reference groups researched: healthy in-
dividuals, individuals with benign diseases of the lung
that influence marker levels and in whom the absence of
a malignant disease has been clinically confirmed, and
patients with NSCLC, confirmed by standard clinical di-
agnostic methods. The reference group of benign pulmo-
nary diseases in relation to NSCLC was defined and used
with 95% specificity for determining the cut-off value of
1.72 ng/mL. This was continuously confirmed between
1998 and 200732–38. In addition, higher sensitivity was ac-
hieved by the implementation of an individual approach
to marker level interpretation. First and foremost, kno-
wledge of the influence of population was considered in
every patient. The second most important point is infor-
mation on the patient either currently suffering or hav-
ing previously suffered from a disease that can influence
marker dynamics (such as renal insufficiency, sepsis, he-
patic insufficiency, pleural empyema, hepatorenal syn-
drome, urinary bladder cancer, thyroid carcinoma, colon
cancer, esophageal cancer, breast cancer, larynx cancer,
etc.). The cut-off selected for the Croatian population en-
ables clinicians to make an earlier diagnosis on the basis
of repeating diagnostic procedures. This is further veri-
fied by our patient sample, most of whom are in stage I.
This approach resulted in the standardisation of markers
for lung cancer, its bone metastasis and mesothelioma:
CYFRA 21-1, NSE, ProGRP, ICTP and SMRP32–43. Data
interpretation in clinical laboratories is a systemic and
comparative process of evaluating numerous influences
and their measured value. The findings are a sum of re-
sults, but also a suggestion for further measurements
and the decision-making process20. This is why our mar-
ker value interpretation closely corresponds to clinical
tests and opinions. In other words, the tumour marker
value before therapy contributes to earlier detection and
diagnosis. Value dynamics in longitudinal follow-ups pro-
vides insight into the biological activities of the tumour
in which the marker with its biological inception and/or
degradation participates either with or without the influ-
ence of therapy (Figures 6–9). If there is no biological ac-
tivity in the tumour, then there is no biological pathway
that influences its level, which is, clinically, an indicator
of the stability of the disease. This study shows the first
part of the results of the ten years of the application of
the CYFRA 21-1 tumour marker in suggesting diagnos-
tics and earlier detection. In other words, the marker
was not used as a self-sufficient diagnostic procedure.
The high sensitivity of CYFRA 21-1 in our results con-
firms its contribution to the diagnosis of lung cancer in
general and NSCLC in particular. Similar results have
also been reported by other authors13,27,44–50. In contrast
to these authors, however, our study brings a NSCLC
group much larger in number, type and tumour stage.
So-far studies on the clinical contribution of CYFRA 21-1
vary in sensitivity and specificity depending on the selec-
ted cut-off level ranging between 1.5 ng/mL and 30
ng/mL12–14,17,18,44,46,47,49,51–56.
From 1998 the cut-off was continuously controlled on
a growing number of samples revealing its dynamics in
other tumours and benign diseases, the dynamics of
which differs from the dynamics of NSCLC. Besides the
already known, more benign diseases have been included
in the sample of which it has been discovered that they
influence marker dynamics13,27,57,58. More than half of
the patients are in stage I. Their CYFRA 21-1 sensitivity
ranges between 60 and 81.1% and is in accord with our
so-far results, which have clinically been verified32–40.
The use of the cut-off of 1.72 ng/mL with 95% specificity
facilitates the earlier detection of a larger number of
NSCLCs. In order to analyse sensitivity, tumour size and
extent, NSCLC patients were grouped according to the
TNM classification (IA, IB, IIBT2N1, IIBT3N0, IIIA-
T3N1, IIIAN2, IIIB, IV). At present, there is no publis-
hed study of such a detailed sensitivity analysis. There
are some papers on some of the TNM stages varying in
sensitivity, i.e. from 17% to 89%12,16,49,52,54,59. The lowest
values are recorded in LCC and AD and the highest in
SQC, which corresponds to the results of this study. What
first explains the above variation in other authors is the
following: small groups and NSCLC not being divided in-
to subtypes or stages, i.e. a non-representative patient
sample lacking some stages from I to IV, which are nor-
mally included in routine measurements of the NSCLC
marker. The second important reason is the selected cut-
-off, which depends on the reference group within the re-
ference population, most often including benign lung dis-
eases. Typical specificity is then 95%13,14,16,44,49,51–53,59–62.
Specificities range between 14% and 100% depending on
the reference population12,14,54,55,56. The sensitivity and
specificity results of this study have been confirmed by
clinical diagnostic methods.
The marker has a diagnostic value only if it confirms
the clinical diagnosis. This particularly applies to differ-
ential diagnosis and to distinguishing NSCLC from other
diseases that conceal or coexist with it, or conceal lung
metastases originating from other organs (e.g. pleural
empyema, SCLC, SQC of the larynx, oesophagus and uri-
nary bladder, and breast cancer). This is the greatest
problem with serum markers. With this in mind, we have
examined all the benign and malignant diseases that in-
fluence marker levels during either short or long periods.
The CYFRA 21-1 cut-off for the population of Croatia is
the result of a research of its levels in selectively chosen
R. Pavi}evi} et al.: CYFRA 21-1 in Non-Small Cell Lung Cancer, Coll. Antropol. 32 (2008) 2: 485–498
494
groups with the aim to separate the diseases that either
limit or influence its increased levels. For the purpose of
determining the cut-off, subjects with benign pulmonary
diseases and diseases of other organs as well as with
NSCLC were included. Groups of subjects who at first ex-
hibited a mild to moderate increase in their CYFRA 21-1
levels, which dropped either in repeated measurements
(within 3 to 9 weeks) or during treatment (of hemoptysis,
pulmonary pneumopathy with severe cough, empyema,
severe extrinsic asthma, advanced COPD, septic condi-
tions, advanced hepatorenal syndrome, etc.) were not in-
cluded in the research. In addition, measurements taken
during invasive procedures (i.e. bronchoscopy, oesopha-
goscopy, drainage, diagnostic VATS, mediastinoscopy and
thoracotomy) were also excluded. Any invasive proce-
dure on the bronchial tree leads to an increase in CYFRA
21-1 levels, which is the result of the injured epithelium’s
release that lasts 14 days at the most. For instance, in
postpneumonic empyema the CYFRA 21-1 level is up to
twenty times higher than the cut-off value before drain-
age and therapy; within a few days, following drainage
and therapy, the CYFRA 21-1 level drops down to the ref-
erential range of the population. Similarly, in late pos-
tpneumonectomy empyema following lung cancer sur-
gery, the CYFRA 21-1 level is again up to twenty times
higher than the cut-off value, indicating a possible, yet
inexistent relapse; after drainage and an antibiotic ther-
apy it drops down to the referential range of the popula-
tion within ten days. This is why the control groups of
healthy individuals and subjects with benign pulmonary
diseases were carefully selected, which is best substanti-
ated by ROC curves, as well as by clinical confirmations
of early diagnoses. The development of malignant disea-
ses of other organs can result in an excessive release of
cytokeratin 19 into the circulation. In some diseases the
CYFRA 21-1 level is mildly increased, but clinically use-
less due primarily to an insufficient sensitivity and speci-
ficity. Nevertheless, it must not be neglected. Thus, mea-
suring the CYFRA 21-1 level would be highly useful in
SCLC, mesothelioma and particularly in larynx, oesopha-
gus, urinary bladder and breast cancer, and endobron-
chial metastases originating from other organs. Research
on its clinical applicability on a larger sample is currently
being conducted. The above makes CYFRA 21-1 an una-
voidable clinical parameter in making an earlier diagno-
sis of NSCLC. The sensitivity obtained in our sample is
still insufficient to compensate for the deficiencies of cli-
nical diagnosis. Thus, in order to increase the sensitivity,
a biodynamic approach was implemented and CYFRA
21-1 levels were measured twice preceding clinical diag-
nosis (in patients whose CYFRA 21-1 levels were lower
than 1.72 ng/mL). It shows a difference in the levels
which is greater in stage I NSCLC patients than in
healthy subjects, certain benign lung diseases, malignant
diseases of other organs and lung metastases originating
from other organs. There is no significant statistical dif-
ference between the two measurements in lung metasta-
ses originating from other organs, while in primary lung
cancers there is. This only confirms the existence of bio-
logical differences between primary and secondary lung
tumours. The difference in the values obtained in two
measurements in primary lung tumours shows the great-
est discriminatory power in separating NSCLC from ot-
her pulmonary nodules39. The use of tumour markers
has shortened the period between two checkups, which
ultimately means that a diagnosis can be made earlier.
The increase of CYFRA 21-1 levels between two measu-
rements (within 3 to 9 weeks) in solitary lung nodules
confirms the diagnosis and facilitates the earlier treat-
ment of stage IA NSCLC.
How much time should optimally pass between the
two measurements is determined by laboratory physi-
cians depending on tumour size and structure, and the
level of CYFRA 21-1. With this in mind, close attention
was given to tumour type and the structure of tumour
mass. In some stages of tumour development, particu-
larly in the development of necroses with colliquation,
lower CYFRA 21-1 values were measured, i.e. mostly
around the maximum of the reference population. The
values within the reference range dominated in stages IA
and IB (0.1–1.4 ng/mL), while in stages IB to IV they ran-
ged between 0.3 and 4.7 ng/mL. Accordingly, lower sensi-
tivity has been expected in some patients, which our re-
search confirmed. In such instances, NSCLC was not
excluded from the findings. Instead, measurements were
repeated within 3 to 9 weeks. What was taken account of
was the fact that some patients with central necrosis of
lung cancer frequently have isolated metastases in other
organs. In addition, in T2N0M1 with cerebral metastases
the marker value does not decrease after removal, but
only after the surgical removal of the primary lung tu-
mour (Figure 9). The contribution of CYFRA 21-1 to dif-
ferential diagnosis (i.e. earlier lung cancer diagnosis and
metastases separation) cannot be disregarded. The inter-
pretation that writes »tumour biological activity registe-
red« either confirms the clinical diagnosis or warns clini-
cians to prove the existence of a tumour within a shorter
period using standard clinical tests. Tumour markers are
not only a contribution to diagnosis, but are also a con-
trol mechanism of other diagnostic methods (upcoming
paper).
Opinions on the mechanism causing the release of
cytokeratin 19 differ greatly. The results of this research
support the fact that SQC’s larger tumour mass necroti-
ses more centrally and produces less cytokeratin, whose
level in the advanced stages of NSCLC does not always
appear to be as high as expected. In advanced stages tu-
mours exhaust the host tissue, diminish, release the
cytokeratin from the remaining decomposing mass and
send signal molecules to other tissues (i.e. metastases).
The fact that in samples of lung metastases the sensitiv-
ity of CYFRA 21-1 was low supports and confirms the
above. Likewise, AD and LCC also contain less cytokera-
tin 19, which confirms the fact that simple epithelia,
such as the bronchial, abound in cytokeratin 19 (besides
cytokeratins 7, 8, 18 and 20), which is why the level of
CYFRA 21-1 is higher in SQC.
Moreover, our results show that the level of CYFRA
21-1 depends on tumour size (Kruskal-Wallis ANOVA
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<10–4). However, this does not exclude some patients
with high CYFRA 21-1 levels, who have pathohistologi-
cally been diagnosed with a lower stage because they
have no lymph node metastases. The reason for this
should be sought in the correlation between the time of
sampling and the time of tumour development. It is im-
portant to underline that tumours in patients exposed to
the same etiological factors and of the same age have dif-
ferent chronologies and types of mechanism of emer-
gence, development and metastasis, which means that
the acquired characteristics of such tumours also differ7.
The statistical significance of CYFRA 21-1 levels be-
fore therapy in stage I SQC and AD verifies that this
marker can indeed distinguish between initial and ad-
vanced stages. The case is similar in IIB T2N1. In NSCLC
the level of CYFRA 21-1 differs significantly between
stage IV and the other stages, then between IIB T3N0
and IIIA T3N1, and between IIIA T3N1 and IIIA N2.
However, this statistical data cannot be accepted clinical-
ly because not all subjects have displayed it (e.g. LCC). It
is crucially important for serum marker findings to mea-
sure the same before therapy during diagnostic manage-
ment. It is proof of a diagnosis, assists therapy selection
and is the basis for understanding the events in the tu-
mour caused by therapy and the control mechanisms of
treatment. In stage IA to IIIA patients, both the tumour
and its necrotic mass were surgically removed respecting
the surgical algorithm so as to allow oncologists to imple-
ment the most efficient adjuvant therapy. Stage IIIA pa-
tients without necrosis first underwent a neoadjuvant
therapy and were only then surgically treated. Keeping
in mind its stage and the total survival rate, surgically
treating NSCLC with extremely high levels of CYFRA
21-1 is indeed questionable. Our results show that in
over 95% of NSCLC patients (our unpublished data) both
the propagation of the disease and the time of death oc-
curred earlier regardless of the modality of treatment. A
significantly increased value of CYFRA 21-1 before sur-
gery confirms the diagnosis, but also indicates the size of
the tumour mass. Higher levels of CYFRA 21-1 were also
obtained in T2–T4. The extent of the tumour (i.e. clinical
N in TNM staging) can be distinguished according to our
results, but cannot always be clinically confirmed.
The findings of the tumour marker CYFRA 21-1 have
significantly contributed to clinical practice facilitating
earlier detection, diagnosis, and therapy selection and
control in NSCLC patients32–40,63, 64.
Conclusion
There is no ideal marker. A sufficiently sensitive and
specific marker can facilitate an earlier clinical diagnosis
to be suggested and the selection of the modality of treat-
ment.
CYFRA 21-1 has been standardised in the Croatian
population and has become part of unavoidable clinical
procedure in NSCLC patients. The cut-off of 1.72 ng/mL
at 95% specificity has been used in clinical application
since 1998 (R. Pavi}evi}) and is confirmed on the sample
presented.
Measuring CYFRA 21-1 twice before making a clinical
diagnosis shows that the level in stage I NSCLCs is hig-
her than in healthy subjects and subjects with certain be-
nign lung diseases. This unusual dynamics of CYFRA
21-1 prompts clinicians to repeat clinical diagnostic pro-
cedures in order to confirm the diagnosis.
Furthermore, the measurement of CYFRA 21-1 levels
allows the separation of NSCLC from lung metastases
originating from other organs, except intraluminal bron-
chial metastases. However, lung cancer metastases to ot-
her organs cannot be verified.
The sensitivity of CYFRA 21-1 is 78% in NSCLC pa-
tients (75–97% in SQC, 60–94% in AD and 60–100% in
LCC).
An increase in CYFRA 21-1 levels is a signal of biolog-
ical activity in NSCLC, which prompts clinicians to con-
firm the disease and make the diagnosis. This is achieved
by repeating standard clinical methods.
With the help of CYFRA 21-1 levels, NSCLC can be
distinguished according to its histological type, and ac-
cording to the T and N classification, particularly SQC,
and the initial from the advanced stages. This cannot be
applied without comparison to clinical findings.
Measuring marker levels before therapy and during
diagnostic management is of crucial importance for the
interpretation of serum marker dynamics.
Considering that it is a serum marker, CYFRA 21-1
cannot be a screening marker.
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CYFRA 21-1 U KARCINOMU PLU]A NEMALIH STANICA
– STANDARDIZACIJA I PRIMJENA U VRIJEME DIJAGNOZE
S A @ E T A K
Za sada nema idealnog tumorskog markera. Klini~ka primjena CYFRA 21-1 mogu}a je nakon temeljito provedenog
postupka standardizacije koju ~ini odre|ivanje referentnog raspona u asimptomatskoj populaciji, benignim i malignim
bolestima plu}a, te benignim i malignim bolestima drugih organa. Ovaj postupak ovisi o poznavanju karakteristika is-
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tra`ivane populacije, anamnesti~kih podataka i nalaza dijagnosti~kih postupaka kod svakog pacijenta, veli~ini ciljano
odabranog uzorka i klini~ki definiranih kontrolnih grupa. Referentna razina (engl. cut-off) CYFRA 21-1 kod karcinoma
nemalih stanica plu}a (NSCLC) u Hrvatskoj populaciji iznosi 1,72 ng/ml. Bazira se na klini~ki primjenjivoj senzitivnosti
78% i specifi~nosti 95% kod benignih bolesti plu}a. Vrijednost referentne razine je potvr|ena u klini~kim nalazima. Ra-
zina CYFRA 21-1 ranije ukazuje klini~aru na NSCLC u odnosu na sve benigne bolesti plu}a i drugih organa za koje smo
utvrdili da mogu utjecati na razinu, ukoliko se potvrdi standardnim dijagnosti~kim metodama. Na CYFRA 21-1 utje~e i
vrijeme uzimanja uzoraka u odnosu na druge dijagnosti~ke invazivne postupke. Klini~ki primjenjiv marker ima potvr-
du u klini~kim nalazima, ina~e je beskoristan. U ovom radu su obuhva}ene 343 zdrave osobe te pacijenti s 474 benigne
bolesti i 4.440 malignoma od ~ega je 2.453 NSCLC. Senzitivnost CYFRA 21-1 kod NSCLC je 78%, u karcinomu skva-
moznih stanica plu}a 84,6 %, adenokarcinomu plu}a 74,3 % i karcinomu velikih stanica plu}a 75,3 %. Razina CYFRA
21-1 se zna~ajno razlikuje izme|u zdravih, benignih i malignih bolesti (p<10–3). Razlike postoje izme|u tri histolo{ka
tipa NSCLC (p<10–6) te T i N izme|u histolo{kih tipova (p<10–3). CYFRA 21-1 upu}uje klini~are da ponavljanim pos-
tupcima u doba dijagnoze ranije detektiraju bolest i zapo~nu lije~enje pacijenata s NSCLC. Na{i nalazi markera su u vi-
sokom podudaranju s dijagnostikom.
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